medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 3

<< Back

Ann Hepatol 2018; 17 (3)

The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report

Smolders EJ, Willemse SB, El-Sherif O, Khoo S, Burger DM

Language: English
References: 27
Page: 525-529
PDF size: 136.49 Kb.


ABSTRACT

Chronic hepatitis C virus (HCV) infection can be cured with treatment using direct-acting antivirals (DAAs). Although these drugs have been widely studied, information about certain special populations is missing. In this case report we describe a treatment-experienced patient with chronic HCV infection genotype 1b, treated with 150 mg/day simeprevir, 400 mg/day sofosbuvir, and 1,000 mg/ day ribavirin for 24 weeks, after a Roux-and-Y gastric bypass. At steady-state a pharmacokinetic curve was recorded of sofosbuvir, GS-331007, and simeprevir. Ribavirin trough plasma concentration (Ctrough) was determined. The simeprevir area under the-concentration time curve (AUClast) and Ctrough were 9.42 h.mg/L and 0.046 mg/L, respectively. Compared to what was described in the literature, simeprevir exposure was low and therefore the simeprevir dose was increased to 300 mg/day. The increased dose of simeprevir was well tolerated and Ctrough was 0.532 mg/L. Sofosbuvir AUClast and Ctrough were 0.63 h.mg/L and 0.0013 mg/L. GS- 331007 AUClast and Ctrough were 21.02 h.mg/L and 0.35 mg/L. Ribavirin Ctrough was 2.5 mg/L. Sofosbuvir, GS-331007, and ribavirin exposure were comparable with levels described in literature. The patient achieved a sustained virological response twelve weeks after the completion of treatment.


REFERENCES

  1. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes Surg 2009; 19: 1605-11. Doi: 10.1007/ s11695-009-0014-5.

  2. Angrisani L, Santonicola A, Iovino P, Formisano G, Buchwald H, Scopinaro N. Bariatric Surgery Worldwide 2013. Obes Surg 2015; 25: 1822-32. Doi: 10.1007/s11695-015-1657-z.

  3. World Health Organization. Fact sheet #311: Obesity and overweight. Available at: http://www.who.int/mediacentre/ factsheets/fs311/en/. Access: April 6 2017.

  4. Sinha A, Jayaraman L, Punhani D, Chowbey P. Enhanced Recovery after Bariatric Surgery in the Severely Obese, Morbidly Obese, Super-Morbidly Obese and Super-Super Morbidly Obese Using Evidence-Based Clinical Pathways: a Comparative Study. Obesity Surgery 2016; 1-9. Doi: 10.1007/s11695-016-2366-y.

  5. Pawlotsky JM, Aghemo A, Back D, Dusheiko G, Forns X, Negro F, Puoti M, et al. EASL Recommendations on Treatment of Hepatitis C 2016 [In press]. J Hepatol 2016. Doi: http:// dx.doi.org/10.1016/j.jhep.2016.09.001.

  6. EMA. Daklinza: Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/003768/ WC500172848.pdf. Access: February 15 2015.

  7. EMA. Olysio: Summary of Product Characteristics. Available at: http://ec.europa.eu/health/documents/community-register/ 2014/20140514128513/anx_128513_en.pdf. Access: February 15 2015.

  8. EMA. Viekirax: Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/003839/ WC500183997.pdf. Access: June 5 2015.

  9. EMA. Rebetol Product Information. Available at: http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000246/WC500048210.pdf. Access: March 02 2016.

  10. EMA. Harvoni: Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Product_Information/human/ 003850/WC500177995.pdf. Access: February 15 2015.

  11. EMA. Summary of Product characteristics Epclusa. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/ E P A R _ - _ P r o d u c t _ I n f o r m a t i o n / h u m a n / 0 0 4 2 1 0 / WC500211151.pdf. Access: 8 december 2016.

  12. Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, Schiff E, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 2016; 64: 370-80. doi: 10.1002/hep.28467.

  13. Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, Godofsky E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 2016; 64: 360-9. doi: 10.1002/hep.28422.

  14. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Ledinghen V, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54. Doi: 10.1002/hep.20506.

  15. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13.

  16. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.

  17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93. doi: 10.1002/ hep.510240201.

  18. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74. doi: 10.1111/j.1572- 0241.1999.01377.x.

  19. Pawlotsky JM, Aghemo A, Back D, Dusheiko G, Forns X, Puoti M, Sarrazin C, et al. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236.

  20. Arends JE, Berden FA, Brouwer JT, Burger DM, Drenth JPH, Hoepelman AIM, Honkoop P, et al. Richtsnoer behandeling hepatitis C infectie. Available at: http:// www.hcvrichtsnoer.nl/. Access: November 01 2016.

  21. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http:// www.hcvguidelines.org. Access: February 14 2015.

  22. Slavenburg S, Huntjens-Fleuren HW, Dofferhoff TS, Richter C, Koopmans PP, Verwey-Van Wissen CP, Drenth JP, et al. Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations. Ther Drug Monit 2011; 33: 40-4.

  23. D'Avolio A, Ibanez A, Sciandra M, Siccardi M, de Requena DG, Bonora S, Di Perri G. Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. J.Chromatogr.B Analyt.Technol.Biomed. Life Sci 2006; 835: 127-30.

  24. Manns M, Reesink H, Berg T, Dusheiko G, Flisiak R, Marcellin P, Moreno C, et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype- 1 patients: a randomized trial. Antivir Ther 2011; 16: 1021-33. doi: 10.3851/imp1894.

  25. de Kanter CT, Buti M, DeMasi R, Ouwerkerk-Mahadevan S, Dofferhoff AS, Witek J, Drenth JP, et al. Ribavirin concentration determines treatment success of first-generation DAAbased chronic HCV therapy. Antivir Ther 2016; 21: 153-9. doi: 10.3851/imp2994.

  26. EMA. Sovaldi Product Information. Available at: http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/002798/WC500160597.pdf. Access: February 29 2016.

  27. Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Clin Pharmacokinet 2015; 54: 677-90. doi: 10.1007/s40262- 015-0261-7.




2020     |     www.medigraphic.com